Quality Tissue Converting Company Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-12-2024
- Paid Up Capital ₹ 0.10 M
as on 09-12-2024
- Company Age 19 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 64.79%
(FY 2022)
- Profit 109.14%
(FY 2022)
- Ebitda 24.82%
(FY 2022)
- Net Worth 7.17%
(FY 2022)
- Total Assets 31.56%
(FY 2022)
About Quality Tissue Converting Company
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jagadish Patil, Anil Kumar, and Shrihari Waychal serve as directors at the Company.
- CIN/LLPIN
U21029PN2004PTC020062
- Company No.
020062
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Dec 2004
- Date of AGM
25 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Quality Tissue Converting Company?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Kumar  | Director | 01-Sep-2010 | Current |
| Jagadish Patil | Director | 01-Apr-2023 | Current |
| Shrihari Waychal | Director | 01-Apr-2023 | Current |
Financial Performance and Corporate Structure Insights of Quality Tissue Converting Company.
Quality Tissue Converting Company Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 64.79% increase. The company also saw a substantial improvement in profitability, with a 109.14% increase in profit. The company's net worth moved up by a moderate rise of 7.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Quality Tissue Converting Company?
In 2020, Quality Tissue Converting Company had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dipper Healthcare Private LimitedActive 17 years 5 monthsAnil Kumar and Shrihari Waychal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Quality Tissue Converting Company?
Quality Tissue Converting Company has a workforce of 42 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Quality Tissue Converting Company, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Quality Tissue Converting Company's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
